How Does Pharmacogenetics Affect IV to PO Tacrolimus Conversion?
The Clinical Pharmacogenetics Implementation Consortium guides dosing of tacrolimus based on CYP3A5 phenotype. Tacrolimus is primarily metabolized by CYP3A5 and CYP3A4 and is actively transported by ABCB1. Unlike the case with other CYP enzymes, the absence of functional CYP3A5 expression is the norm. Read more.

Assessing Safety of Biological Home-Infusions Agents for IBD
The use of biological agents to manage inflammatory bowel disease (IBD; i.e., Crohn's disease and ulcerative colitis) has grown markedly in recent years. As the concept of patient-centered medical and home-care services has expanded, patients are no longer receiving these infusions just at conventional infusion centers; they are also receiving them at home. Read more.

Cetirizine Equally Effective, Safer Alternative to Diphenhydramine?
IV diphenhydramine has been considered the standard of care for hypersensitivity infusion reactions. However, IV diphenhydramine has an adverse-event (AE) profile that includes potent anticholinergic effects, and it is a Beer's list drug, making its use undesirable in older adults. IV cetirizine, approved in 2019 for the treatment of acute urticaria in adults, may offer a more favorable AE profile. Read more.